Mixture survival models methodology: an application to cancer immunotherapy assessment in clinical trials

11/21/2019
by   Lizet Sanchez, et al.
0

Progress in immunotherapy revolutionized the treatment landscape for advanced lung cancer, raising survival expectations beyond those that were historically anticipated with this disease. In the present study, we describe the methods for the adjustment of mixture parametric models of two populations for survival analysis in the presence of long survivors. A methodology is proposed in several five steps: first, it is proposed to use the multimodality test to decide the number of subpopulations to be considered in the model, second to adjust simple parametric survival models and mixture distribution models, to estimate the parameters and to select the best model fitted the data, finally, to test the hypotheses to compare the effectiveness of immunotherapies in the context of randomized clinical trials. The methodology is illustrated with data from a clinical trial that evaluates the effectiveness of the therapeutic vaccine CIMAvaxEGF vs the best supportive care for the treatment of advanced lung cancer. The mixture survival model allows estimating the presence of a subpopulation of long survivors that is 44 differences between the treated and control group were significant in both subpopulations (population of short-term survival: p = 0.001, the population of long-term survival: p = 0.0002). For cancer therapies, where a proportion of patients achieves long-term control of the disease, the heterogeneity of the population must be taken into account. Mixture parametric models may be more suitable to detect the effectiveness of immunotherapies compared to standard models.

READ FULL TEXT

page 1

page 2

page 3

page 4

research
08/01/2019

Teasing out the overall survival benefit with adjustment for treatment switching to other therapies

In oncology clinical trials, characterizing the long-term overall surviv...
research
06/06/2023

survextrap: a package for flexible and transparent survival extrapolation

Health policy decisions are often informed by estimates of long-term sur...
research
11/12/2019

Identifying predictive biomarkers of CIMAvaxEGF success in advanced Lung Cancer Patients

Objectives: To identify predictive biomarkers of CIMAvaxEGF success in t...
research
03/19/2023

A hybrid CNN-RNN approach for survival analysis in a Lung Cancer Screening study

In this study, we present a hybrid CNN-RNN approach to investigate long-...
research
12/15/2021

Informed Bayesian survival analysis

We overview Bayesian estimation, hypothesis testing, and model-averaging...

Please sign up or login with your details

Forgot password? Click here to reset